| Literature DB >> 22110625 |
Alison Booth1, Mike Clarke, Davina Ghersi, David Moher, Mark Petticrew, Lesley Stewart.
Abstract
BACKGROUND: In response to growing recognition of the value of prospective registration of systematic review protocols, we planned to develop a web-based open access international register. In order for the register to fulfil its aims of reducing unplanned duplication, reducing publication bias, and providing greater transparency, it was important to ensure the appropriate data were collected. We therefore undertook a consultation process with experts in the field to identify a minimum dataset for registration. METHODS ANDEntities:
Mesh:
Year: 2011 PMID: 22110625 PMCID: PMC3217945 DOI: 10.1371/journal.pone.0027319
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Number of responses to questionnaires.
| Number on core panel list | Number who started the survey | Core panel collector | Open collector | Number who completed the survey (%) | |
| First round | 315 | 194 | 143 | 51 | 194 (100) |
| Second round | 318 | 209 | 169 | 40 | 190 (91) |
Registration dataset response rates for Delphi round one and two.
| Field title | Delphi first round responses (194) | Delphi second round responses (209) | ||||||
| Essential | Desirable | Not necessary | Agree should be Required*/Optional | Disagree should be Optional/Required* | Disagree, not needed | No opinion | ||
| 1 | Review title | 174 (90%) | 17 (9%) | 3 (2%) | 189 (98%)* | 4 (2%) | 0 (0%) | 0 (0%) |
| 2 | Named contact | 186 (96%) | 5 (3%) | 3 (2%) | 187 (97%)* | 5 (3%) | 0 (0%) | 1 (1%) |
| 3 | Organisational affiliation of the review | 136 (70%) | 51 (26%) | 7 (4%) | 162 (84%)* | 23 (12%) | 1 (1%) | 7 (4%) |
| 4 | Named contact address | 74 (38%) | 91 (47%) | 29 (15%) | 148 (77%) | 30 (16%)* | 9 (5%) | 6 (3%) |
| 5 | Named contact phone number | Item not included in first round | 151 (78%) | 13 (7%)* | 21 (11%) | 8 (4%) | ||
| 6 | Named contact email | 166 (86%) | 26 (13%) | 2 (1%) | 180 (93%)* | 11 (6%) | 0 (0%) | 2 (1%) |
| 7 | Review team | 76 (39%) | 82 (42%) | 36 (19%) | 129 (67%) | 49 (25%)* | 10 (5%) | 5 (3%) |
| 8 | Review team members' sorganisational affiliations | 48 (25%) | 104 (54%) | 42 (22%) | 146 (76%) | 27(14%)* | 12 (6%) | 8 (4%) |
| 9 | Collaborators | 35 (18%) | 106 (55%) | 53 (27%) | 147 (76%) | 18 (9%)* | 19 (10%) | 9 (5%) |
| 10 | Anticipated or actual start date | 125 (64%) | 57 (29%) | 12 (6%) | 170 (89%)* | 18 (9%) | 1 (1%) | 3 (2%) |
| 11 | Anticipated completion date | 91 (47%) | 88 (45%) | 15 (8%) | 152 (79%)* | 33 (17%) | 3 (2%) | 4 (2%) |
| 12 | Anticipated publication date | 36 (19%) | 109 (56%) | 49 (25%) | Item not included in second round | |||
| 13 | Funding sources/sponsors | 155 (80%) | 31 (16%) | 8 (4%) | 179 (93%)* | 12 (6%) | 1 (1%) | 0 (0%) |
| 14 | Conflicts of interest | 152 (78%) | 31 (16%) | 11 (6%) | 173 (90%)* | 14 (7%) | 3 (2%) | 2 (1%) |
| 15 | Other registration details | Item not included in first round | 134 (70%) | 50 (26%)* | 8 (4%) | 0 (0%) | ||
| 16 | Organisation reference number | 55 (28%) | 88 (45%) | 51 (26%) | 139 (72%) | 17 (9%)* | 18 (9%) | 18 (9%) |
| 17 | Language | 110 (57%) | 65 (34%) | 19 (10%) | 103 (54%) | 72 (38%)* | 10 (5%) | 7 (4%) |
| 18 | Country | 67 (35%) | 83 (43%) | 44 (23%) | 136 (71%) | 33 (17%)* | 17 (9%) | 6 (3%) |
| 19 | Key words | 133 (69%) | 47 (24%) | 14 (7%) | 114 (59%) | 69 (36%)* | 6 (3%) | 3 (2%) |
| 20 | Any other information | 30 (16%) | 101 (52%) | 63 (33%) | 170 (89%) | 6 (3%)* | 8 (4%) | 8 (4%) |
| 21 | Review question(s) | 186 (96%) | 6 (3%) | 2 (1%) | 186 (97%)* | 4 (2%) | 1 (1%) | 0 (0%) |
| 22 | Economic Evaluations | 73 (38%) | 85 (44%) | 36 (19%) | Item not included in second round | |||
| 23 | Searches | 131 (68%) | 42 (22%) | 21 (11%) | 155 (81%)* | 32 (17%) | 3 (2%) | 1 (1%) |
| 24 | URL to search strategy | 51 (26%) | 93 (48%) | 50 (26%) | 143 (75%) | 28 (15%)* | 14 (7%) | 6 (3%) |
| 25 | Types of study to be included | 167 (86%) | 23 (12%) | 4 (2%) | 167 (87%) | 21 (11%) | 3 (2%) | 0 (0%) |
| 26 | Condition or domain being studied | 150 (77%) | 35 (18%) | 9 (5%) | 177 (93%) | 11 (6%) | 3 (2%) | 0 (0%) |
| 27 | Participants/population | 176 (91%) | 14 (7%) | 4 (2%) | 178 (93%) | 12 (6%) | 1 (1%) | 0 (0%) |
| 28 | Intervention(s), exposure(s) | 176 (91%) | 15 (8%) | 3 (2%) | 184 (96%) | 6 (3%) | 1 (1%) | 0 (0%) |
| 29 | Comparator(s)/control | 168 (87%) | 24 (12%) | 2 (1%) | 180 (94%) | 9 (5%) | 1 (1%) | 1 (1%) |
| 30 | Context | 99 (51%) | 77 (40%) | 18 (9%) | 106 (56%) | 77 (40%) | 3 (2%) | 5 (3%) |
| 31 | Primary outcome(s) | 180 (93%) | 13 (7%) | 1 (1%) | 177 (93%) | 11 (6%) | 3 (2%) | 0 (0%) |
| 32 | Effect measures for primary outcome(s) | 126 (65%) | 51 (26%) | 17 (9%) | (Merged with item 31) | |||
| 33 | Secondary outcome(s) | 130 (67%) | 55 (28%) | 9 (5%) | 146 (76%) | 38 (20%) | 5 (3%) | 2 (1%) |
| 34 | Effect measures for secondary outcome(s) | 82 (42%) | 88 (45%) | 24 (12%) | (Merged with item 33) | |||
| 35 | Data extraction, (selection and coding) | 100 (52%) | 58 (30%) | 36 (19%) | 102(53%) | 76 (40%) | 11 (6%) | 2 (1%) |
| 36 | Risk of bias (quality) assessment | 118 (61%) | 54 (28%) | 22 (11%) | 142 (74%) | 35 (18%) | 11 (6%) | 3 (2%) |
| 37 | Strategy for data synthesis | 131 (68%) | 46 (24%) | 17 (9%) | 136 (71%) | 41(22%) | 10 (5%) | 4 (2%) |
| 38 | Methods for exploring heterogeneity 1 | 93 (48%) | 67 (35%) | 34 (18%) | (Merged with 35 and 36 into item 37) | |||
| 39 | Methods for exploring heterogeneity 2 | 78 (40%) | 76 (40%) | 40 (20%) | (Merged with 34 and 36 into item 37) | |||
| 40 | Definition and rationale for use of specific techniques | 73 (38%) | 71 (37%) | 50 (26%) | (Merged with 34 and 35 into item 37) | |||
| 41 | Analysis of subgroups or subsets | (Presented in items 34, 35, 36 in first round) | 134 (70%) | 42 (22%) | 10 (5%) | 5 (3%) | ||
| 42 | Dissemination plans | 35 (18%) | 98 (51%) | 61 (31%) | 151 (79%) | 10 (5%) | 24 (13%) | 6 (3%) |
| 43 | Details of any existing review of the same topic by the same authors | 139 (72%) | 39 (20%) | 16 (8%) | 124 (65%) | 54 (28%) | 8 (4%) | 5 (3%) |
The majority of respondents in round one selected this as ‘essential’.
How heterogeneity will be explored. Under what circumstances will a meta-analysis be considered appropriate.
Covariates to be explored with method of analysis.
PROSPERO dataset.
|
| ||
| 1 |
| The working title of the review. |
| 2 |
| The working title in the language of the review where this is not English. |
| 3 |
| The date when the systematic review commenced, or is expected to commence. |
| 4 |
| The date by which the review is expected to be completed. |
| 5 |
| The stage of progress of the review at the time of initial registration. |
|
| ||
| 6 |
| The named contact acts as the guarantor for the accuracy of the information presented in the Register record. |
| 7 |
| The electronic mail address of the named contact. |
| 8 |
| The full postal address for the named contact. |
| 9 |
| The telephone number for the named contact, including international dialling code. |
| 10 |
| Names of all members of the review team and their organisational affiliations. |
| 11 |
| Details of the organisational affiliations for this review. |
| 12 |
| Details of the individuals, organizations, groups or other legal entities who take responsibility for initiating, managing, sponsoring and/or financing the review. |
| 13 |
| Any conditions that could lead to actual or perceived undue influence on judgements concerning the main topic investigated in the review. |
| 14 |
| The name, affiliation and role of any individuals or organisations who are working on the review but who are not listed as review team members. |
|
| ||
| 15 |
| The question(s) to be addressed by the review. |
| 16 |
| Details of the sources to be searched, and any restrictions (e.g. language or publication period). |
| 17 |
| A link to the search strategy or an example of a search strategy for a specific database. |
| 18 |
| A short description of the disease, condition or healthcare domain being studied, including health and wellbeing outcomes. |
| 19 |
| Summary criteria for the participants or populations being studied by the review. The preferred format includes details of both inclusion and exclusion criteria. |
| 20 |
| Full and clear descriptions of the nature of the interventions or the exposures to be reviewed. |
| 21 |
| Details of the alternatives against which the main subject/topic of the review will be compared. |
| 22 |
| Details of the study designs to be included in the review. If there are no restrictions on the types of study design eligible for inclusion, this should be stated. |
| 23 |
| Summary details of the setting and other relevant characteristics which help define the inclusion or exclusion criteria. |
| 24 |
| The most important outcomes, including information on timing and effect measures, as appropriate. |
| 25 |
| Any additional outcomes that will be addressed, including information on timing and effect measures, as appropriate. |
| 26 |
| The procedure for selecting studies for the review and extracting data, including the number of researchers involved and how discrepancies will be resolved. |
| 27 |
| Whether and how risk of bias will be assessed, how the quality of individual studies will be assessed, and whether and how this will influence the planned synthesis. |
| 28 |
| The planned general approach to be used, for example whether the data to be used will be aggregate or at the level of individual participants, and whether a quantitative or narrative (descriptive) synthesis is planned. |
| 29 |
| Any planned exploration of subgroups or subsets within the review. ‘None planned’ is a valid response if no subgroup analyses are planned. |
|
| ||
| 30 |
| The type of review. |
| 31 |
| The language(s) in which the review is being written and will be made available. |
| 32 |
| The country or countries in which the review is being carried out. |
| 33 |
| Other places where the systematic review is registered (such as with The Cochrane Collaboration, The Campbell Collaboration, or The Joanna Briggs Institute). |
| 34 |
| The citation and link for the published protocol, if there is one. |
| 35 |
| Brief details of plans for communicating essential messages from the review to the appropriate audiences. |
| 36 |
| The words or phrases that best describe the review. |
| 37 |
| Details of earlier versions of the systematic review if an update of an existing review is being registered, including full bibliographic reference if possible. |
| 38 |
| Indicate the current status of the review. |
| 39 |
| Any further information the review team consider relevant to the registration. |
| 40 |
| The full citation for the final report or publication of the systematic review, including the URL where available. |
*Indicates a required field.